Zachariah DeFilipp
Blood and Marrow Transplant Program · Massachusetts General Hospital Cancer Center
Credentials: · · · · · · ·
History
- 2016–Present
Massachusetts General Hospital Cancer Center
- 2012–2013
Western Pennsylvania Allegheny Health System
- 2010
Tel Aviv University's Sackler School of Medicine
Research
Drug-Resistant E. coli Bacteremia Transmitted by Fecal Microbiota Transplant
Case report · New England Journal of Medicine · 2019 · First of 10 authors · 1,001 citations
Blood · 2021 · 295 citations
Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma
Blood · 2019 · 201 citations
46 papers
- BS
33 papers
- YI
32 papers
26 papers
- SM
24 papers
- TS
24 papers
23 papers
23 papers
Clinical trials
- 2024–2027
Ziftomenib Maintenance Post Allo-HCT
Principal investigator · Recruiting · Phase 1
Massachusetts General Hospital
- 2021–2026
Inqovi Maintenance Therapy in Myeloid Neoplasms
Principal investigator · Active not recruiting · Phase 1
Massachusetts General Hospital
- 2021–2023
FMT In High-Risk Acute GVHD After ALLO HCT
Principal investigator · Completed · Phase 1
Massachusetts General Hospital
- 2020–2024
Haplo Peripheral Blood Sct In GVHD Prevention
Principal investigator · Completed · Phase 1
Zachariah Michael DeFilipp